System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Céline Blaye is an expert in Allergy at University of Bordeaux (France). Céline Blaye has authored 10 publications, the most recent in 2023, and is an investigator in 2 clinical trials. SLR score: 55 (community average: 125). How the SLR is computed.

LeadR Profile

Céline Blaye University of Bordeaux France
55 ScienceLeadR Reputation 55

Unlock

Register Login
Network Map

Allergy

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2016 - 2023
Source: PubMed

University of Bordeaux

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 10

Citations

Citations: 145 1st author: 6 Last author: 0 Unique author: 0

Main journals

ESMO Open 2
Ann Oncol 1
Breast J 1
Cells 1
Front Immunol 1

Best Journals

Ann Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity.
PMID 37894728 — immunity, estrogens, hormones, immunotherapy, receptors, estrogen, therapeutics, breast neoplasms		Int J Mol Sci202313
An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy.
PMID 35759853 — neoplasm, residual, risk, prognosis, drug therapy, triple negative breast neoplasms, cells, therapeutics, genes, chemotherapy		ESMO Open202211
Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical Perspectives.
PMID 35159363 — immunosuppression therapy, carcinogenesis, macrophages, immunotherapy, neoplasms, immunomodulation, myeloid cells		Cells20223
Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers.
PMID 35309358 — immunity, immune system diseases, immunosuppression therapy, immunotherapy, breast neoplasms, myeloid cells, tumor microenvironment		Front Immunol20227
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
PMID 33895695 — diagnosis, triple negative breast neoplasms, therapeutics		ESMO Open202195

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 1
Phase 3 1

By status:

Unknown 2

By type:

Interventional 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 1
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS